Latest From Naia Ltd.
The numerous different targets of investigational drugs for the treatment of NASH suggest the jury is still out on which mechanism of action is most likely to prove effective against the condition. Ireland’s Afimmune is the latest company wanting to advance an investigational drug for the disorder into late-stage clinical studies.
Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.
In Q1 2015 start-ups raised $2.74 billion, a new record. Biopharma companies penned 37 alliances; 13 start-ups were acquired across all industries.
The diabetes market presents competitive, commercial, and regulatory challenges, but its size and breadth spur emerging biotechs to develop an ever-wider range of treatments and technologies.
- Large Molecule
- Therapeutic Areas
- Metabolic Disorders
- Cayman Islands
- North America
- Company Type
- Parent & Subsidiaries
- Naia Ltd.
- Senior Management
H. Daniel Perez, MD, Chmn. & CEO
Mark Bagnall, CFO & COO
David N Chernoff, MD, CMO
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.